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Multiple myeloma survival has significantly improved in the latest years due to a broad spec-
trum of novel agents available for treatment. The introduction of thalidomide, bortezomib,
and lenalidomide together with autologous stem-cell transplantation has considerably
increased complete remission rate and progression-free survival resulting ultimately in
prolonged survival in myeloma patients. Moreover, novel strategies of treatment such as
consolidation and maintenance are being used to further implement responses. Finally, a
number of new drugs such as carfilzomib and pomalidomide are already in clinical practice,
making the future of myeloma patients brighter.
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INTRODUCTION
Multiple myeloma (MM) is a plasma cell malignancy char-
acterized by clonal proliferation of plasma cells in the
bone marrow microenvironment and associated organ damage
(CRAB= increased calcium, renal insufficiency, anemia, bone
lesions) (1). The organ damage is due to a monoclonal protein
produced in the blood or urine. It represents about 10% of hema-
tological cancers and 1% of all cancers. Median age at diagnosis is
70 years. In the last decades, we experienced a great improvement
in myeloma survival both in young and old patients (2, 3). In fact,
5-year relative survival increased from 28.8 to 34.7% and 10-year
relative survival increased from 11.1 to 17.4% between 1990–1992
and 2002–2004. A more evident increase was seen in the age group
younger than 50 years, leading to 5- and 10-year relative survival of
56 and 41% in 2002–2004, and in the age group 50–59 years, lead-
ing to 5- and 10-year relative survival of 48 and 28% in 2002–2004.
By contrast, only moderate improvement was seen in the age group
60–69 years, and no substantial improvement was achieved among
older patients (3). The clinical progresses are related to the intro-
duction of novel agents (bortezomib, thalidomide, lenalidomide)
and especially for young patients, to autologous stem-cell trans-
plantation (ASCT). These approaches resulted in an increased rate
of complete response (CR) that translated into prolonged survival
and improved quality of life. Additionally,peculiar extra medullary
localizations of MM seemed to benefit from novel agents therapy
(4). Nonetheless, a better understanding of plasma cell biology
and myeloma pathways has resulted in the identification of novel
targets for therapy. New agents deriving from already approved
and active agents (such as second- and third generation protea-
some inhibitors, thalidomide, lenalidomide) have been developed
and also new drugs with novel mechanisms of action are under
investigation in clinical trials.
Although advancements have been outstanding in the field of
myeloma, there is still a small group of patients (10–15%) that
has a dismal prognosis, i.e., del 17p and t(4;14) patients, in which
novel therapeutic approaches are urgently warranted (5–7).
INITIAL TREATMENT OF TRANSPLANT ELIGIBLE MYELOMA
PATIENTS
Today patients younger than 65 years are usually eligible for ASCT.
As induction treatment, three or four cycles of therapy are usually
given and less than six cycles are recommended (8).
Induction therapy is given to reduce tumor burden before
stem-cell harvest, and drugs that can compromise hematopoietic
stem-cell collection should be avoided (alkylating agents) (8).
On the basis of the available data from phase II studies, three-
drug combination regimens are considered as the standard of care
for use as induction therapy prior to ASCT. Thalidomide was the
first novel agent compared with vincristine, adriamycin, dexam-
ethasone (VAD) either in combination with dexamethasone or
with dexamethasone and doxorubicin (TAD), the latter with a lit-
tle benefit (9). Data of the most commonly used agents in phase
III trials are summarized in Table 1. The most effective combi-
nations include proteasome inhibitors plus either thalidomide,
lenalidomide, or chemotherapy. Bortezomib in combination with
dexamethasone (VD) was compared with VAD (10) with induc-
tion of CR/near-CR in 15 vs. 6% and overall response rates 79
vs. 63%, respectively. Even after ASCT, responses were confirmed
superior for VD: CR/nCR: 35 vs. 18%. Median progression-free
survivals (PFS) were 36 vs. 30 months with VD vs. VAD, respec-
tively, yet survival that was not superior in the VD arms maybe
due to effective salvage regimens at the time of relapse.
The combination of bortezomib–thalidomide–dexamethasone
(VTD) has proved to be superior to thalidomide–dexamethasone
(TD) as induction therapy before ASCT resulting in a 3-year PFS
of 68% for the VTD arm vs. 56% for the TD arm (11). VTD
was also superior in a Spanish study associated with thalidomide
maintenance (12). The addiction of doxorubicin to bortezomib–
dexamethasone (PAD) was superior to VAD followed by ASCT and
thalidomide maintenance, with a median PFS of 35 vs. 28 months,
respectively (13).
The association of bortezomib as induction therapy with other
one or two drugs showed a superior efficacy in terms of responses,
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Table 1 | Results of phase III trials employing novel agents as induction therapy in young patients.
Therapy N Reponse post-induction Reponse post-ASCT PFS (months) OS
CR/nCR (%) >VGPR (%) CR/nCR (%) >VGPR (%)
VD 121 15 38 35 68 36 NR (3 years)
VTD 241 31 63 71 89 NR NR (3 years)
PAD 413 15 42 49 76 35 NR (5 years)
VTD 130 35 60 46 U 56 NR (4 years)
U, unreported; NR, not reached.
but none showed so far superiority in terms of overall survival
(OS). Phase II trials have showed that the addition of cyclophos-
phamide (VCD) or lenalidomide (VRD) can be feasible with at
least partial remission (PR) in 97 and 100% of patients, respec-
tively (14, 15). In another phase II study, the four drugs com-
bination with bortezomib–dexamethasone–cyclophosphamide–
lenalidomide (VCDR) appeared to be a good induction option
(16) with a CR rate of 25% and a very good partial response
(VGPR) rate of at least 58%.
The novel proteasome inhibitor carfilzomib was also tested
in phase II studies in newly diagnosed patients: in combi-
nation with lenalidomide and dexamethasone (CRd) showed
outstanding responses with CR/nCR in 67% (17). In another
study, Carfilzomib–thalidomide–dexamethasone was given as pre-
transplant induction and post-transplant consolidation and led to
18% CR and 91%>PR (18).
CONSOLIDATION/MAINTENANCE
Therapy consolidation (usually two cycles after ASCT to increase
responses) and maintenance (continuous therapy until progres-
sion) are being explored to improve outcome after ASCT as an
alternative to perform a second autotransplant with the idea to
achieve the same efficacy but with less toxicity. In one study,
VTD consolidation increased CR from 15 to 49% in patients who
had previously achieved VGPR after double ASCT (19). Molec-
ular remissions by allele-specific polymerase chain reaction (AS-
PCR) following VTD treatment had a better outcome: the PFS at
42 months for patients with a low tumor load was 100 vs. 57%
for patients with a higher tumor load after VTD. Another study
confirmed these findings (20). Two cycles of consolidation ther-
apy with TD or VTD were given after the second ASCT. In the
TD arm, consolidation improved the CR rate from 40 to 47%.
In the VTD arm, the CR rate increased from 49 to 61%. Several
studies are ongoing to better evaluate the role of consolidation
therapy.
Maintenance has been explored first with thalidomide and sub-
sequently with lenalidomide (21–23). Six phase III studies have
shown a benefit for thalidomide in terms of response and PFS, but
OS was improved only in two of these trials (24–28). Yet, grade
3–4 polyneuropathy was a major concern (7–19%), inducing 52%
of median discontinuation rate. Lenalidomide is currently consid-
ered as the best candidate for use as maintenance therapy because
of a safer profile. Results from two randomized trials evaluat-
ing lenalidomide maintenance following ASCT have recently been
published. Although an advantage in progression-free survival
was seen in both trials, a benefit in OS for patients receiving
maintenance therapy was observed only in the trial published
by McCarthy et al. (23). However, this benefit was limited to
those patients who had not achieved a CR on their previous
treatment strategy. Questions have been raised about the need
of a maintenance therapy for every myeloma patient (29, 30). In
addition to carefully consider the risk–benefit ratio for a patient
during maintenance therapy (increase of second malignancies),
patient’s quality of life and treatment cost effectiveness should be
also evaluated. These findings highlight the importance of iden-
tifying the optimal duration of therapy and risk factors for this
complication.
INITIAL TREATMENT OF NON-TRANSPLANT ELIGIBLE
MYELOMA PATIENTS
About two-thirds of MM patients are more than 65 years old at the
time of the first diagnosis. Therefore, the majority of patients are
usually not eligible for high-dose therapy followed by ASCT. Espe-
cially in the elderly, the treatment must be individualized because
of their vulnerability that can complicate both the presentation
and management of MM (31, 32). As such, it is mandatory to take
into consideration the “biological” age of the patient not only the
chronologic age, including the evaluation of both the performance
status by score such as Karnofsky scale and the comorbidities by
geriatric score (33). Age-related organ functions and metabolic
changes can contribute to the poor tolerability of treatments as
well as to increased treatment-related adverse events. Due to these
toxicities, dose adjustments are often required with a consequent
reduction of dose intensity that can lead to the poorer outcome
observed frequently in elderly patients. The prolongation of PFS
and OS must remain as initial aims in the management of old MM
patient, although the quality of life should ultimately prevail in the
oldest and fragile ones.
INDUCTION THERAPY: WHAT IS THE BEST TREATMENT?
Achieving at least a VGPR has been demonstrated to be related
to an improvement of the long-term outcome also in the elderly
patients (34). Standard frontline treatment for elderly patients has
been for long time the combination of the oral alkylating agent
melphalan with prednisone (MP). This schedule is well tolerated
even in frail patients and can be administered as outpatient reg-
imen with maintenance of a good quality of life but the overall
response rate obtained is dismal. The introduction of novel agents,
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Table 2 | Main regimens used in elderly MM patients.
Therapy CR (%) PFS (months) OS
MPT 7–23 15–28 28–52 months
VMP 30 24 68% at 36 months
Rd 4 25 76% at 24 months
MPR-R 10 31 70% at 36 months
VMPT-VT 38 35 61% at 60 months
such as thalidomide, lenalidomide, and bortezomib, has led to
better responses also in this setting of patients. Since the CR is an
independent predictor of longer PFS and OS regardless of age and
International Staging System (ISS), a novel agent is recommended
in the induction therapy.
Six randomized studies have compared the efficacy and safety
of the standard MP regimen to the new combination of MP
plus thalidomide (MPT) (35–41). These trials reported an evident
improvement of the overall response rate and the PFS associated
with the MPT regimen with respect to MP, but the advantage
in OS is unclear. There are two meta-analyses of these data that
confirmed a significant improvement in PFS (5.4 months) and a
“trend” toward significant improvement in OS (6.6 months) when
thalidomide is added to MP as a frontline treatment in elderly
patients (42). In addition, the improvement seems to be less pro-
nounced in patients aged 75 years and the optimal dose of thalido-
mide is not established as most of the clinicians adapted the dose
according to patient’s status and occurrence of side effects or tox-
icity. At least 75% of the grade 3–4 toxicities occurred during the
first 6 months of treatment. Neuropathy, deep-vein thrombosis,
and dermatological toxicity were the most frequent thalidomide-
related adverse events, while hematologic toxicities seemed to be
related to melphalan doses.
Cyclophosphamide is another alkylating agent that can be asso-
ciated with thalidomide and this association achieved an improve-
ment in overall response rate compared to the standard MP (64
vs. 33% respectively), but in terms of PSF and OS there are no
differences between the two regimens (43).
A randomized phase III study compared bortezomib–
melphalan–prednisone (VMP) to MP also in the elderly. VMP
significantly increased the CR rate (from 4 to 30%), PFS (from
16 to 23 months), and OS (from 43 to 56 months) with respect
to MP (44). Subsequently, a reduced bortezomib schedule (from
twice- to once-weekly administration) was shown to be better tol-
erated without affecting the outcome (45). Today, both MPT and
VMP are considered the standard therapies for elderly patients
(Table 2).
More recently, a phase III trial compared lenalidomide plus
high-dose dexamethasone (RD) to lenalidomide plus low-dose
dexamethasone (Rd) in newly diagnosed MM patients. Rd induced
a significantly longer 1-year OS and a lower toxicity compared
to RD (46). The three-drugs regimen melphalan–prednisone–
lenalidomide followed by lenalidomide maintenance (MPR-R)
was lately compared to MPR and MP in a phase III trial. In this
study, MPR-R significantly reduced the risk of progression with
respect to MPR and MP. The CR rate was 10% for MPR-R and
3% for both MPR and MP. MPR-R also significantly prolonged
median PFS (31 vs. 14 vs. 13 months, respectively) (47).
Bortezomib plus thalidomide (VT) maintenance was assessed
in two trials (48, 49). In both studies, PFS was improved although
OS only in one.
CONCLUSION
Many new treatments are now available for MM patients both
transplant-related and non-transplant-related and a continuous
improvement in disease free and OS is expected with the advent
of the newest drugs. If prolongation of OS should be always the
first aim of treatment in the management of elderly and fragile
patients, quality of life should be carefully evaluated.
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